Charging Bulls

[AspenTrader]

You really don't wanna miss out on GYST...

[AspenTrader]

Tons of news released last week for GYST

[TK7j]

Looks like bad news here, we'll see how the market drops, Dow +L119 atm.. Bad cuz moderatly low expectation on fed rate uuughhkkk til 2013!!?? Ye right, that is deeply underestimating the engine of USA employers Oh GIMME A BREAK EVERY WORD IS MODERATE MODERATLY

[Bruce the Stock Guy]

Looks like a double to me>>>>http://stockcharts.com/h-sc/ui?s=RPPR

[Bruce the Stock Guy]

Grabbed a few IMWL

[Bruce the Stock Guy]

NBRI(.063)Things are looking good>>>>http://www.northbayresources.com/

[snowgator69]

HBRM has tremendous potential. Volume is always key in trading any stock and HBRM is definately attracting significant volume these days.

[decouverte d Elbe]

Sometimes. But thanks,buying more BEDA.

[Mt. Blanc]

LOL...They are cleaning her up for the next runner...

BGNN??? Any more weak sellers??? Poor buggers taken out on a slide!

[Bruce the Stock Guy]

BGNN is a hot tamale! <<<<<You're right again Lars..No joke..You have a gift of picking big winners on a regular basis!

[decouverte d Elbe]

BGNN is a hot tamale!

[Bruce the Stock Guy]

BGNN up over 80%!! <muttering..I should have listened!>

[Bruce the Stock Guy]

Percolating over..BREAKOUT MODE!

[decouverte d Elbe]

BGNN is just percolating now; wait till next week, whoa boy!

[MadeIt]

Welcome. BGNN is a steal under .003.

[MadeIt]

Agreed. Nice play

[decouverte d Elbe]

Go COWI (minus E) yes! Thin also!

[mgland]

COWIE loosing E. 9.25 million OS. Looking good

[johnfrasier]

I'm new to this one. Is BGNN a good buy at the current price?

[Bruce the Stock Guy]

What's your average on beda <<<<<0013

[Chicago Trader]

What's your average on beda

[Bruce the Stock Guy]

BGNN..Looks like support @ 0023..BEDA tapping lightly on the 0015 door right now..Will eventually be like a DEA style assault on that same door and a BUST OUT to the mid 2's!

[Chicago Trader]

It means....you are my right hand man who needs to get the boardmarks up to 1000, so we can all start making some dough

[Bruce the Stock Guy]

Now you need to buy 50 million shares of bgnn for me. <<<<Thats it? You're easy..<Looking for proper entry>

[Chicago Trader]

Now you need to buy 50 million shares of bgnn for me. Thanks :)

[Bruce the Stock Guy]

You put my name right next to yours Chitown..Does that mean I'm your main man now?

[Bruce the Stock Guy]

SWEET!

[Chicago Trader]

We welcome bruce gorman to our board

[Bruce the Stock Guy]

BGNN and BEDA TWO BIG PICKS for this week<<<<<LOADED to the gills on BEDA and looking for an entry on BGNN..

[decouverte d Elbe]

BGNN and BEDA TWO BIG PICKS for this week. Get in today!!

[decouverte d Elbe]

Good morning! Time to start the best board on IHUB here!

[MadeIt]

Check out BGNN.

[Bruce the Stock Guy]

OK..Lets get some BEDA..ITS READY!

[decouverte d Elbe]

Yes, let's start charging!

[Bruce the Stock Guy]

Lets wake up the Charging Bulls!

[decouverte d Elbe]

Cowie, and WAMU..looking ready to pop!

[MadeIt]

FVSTA...low floater

[decouverte d Elbe]

FTER BGNN WAMUQ ENTI good plays today

[MadeIt]

FVSTA Daily Chart

[MadeIt]

FVSTA is looking primed and ready to run

[decouverte d Elbe]

News! Friday via transfer agent O/S FTER 15,324,866
Transfer Agent Information
Corporate Stock Transfer, Inc.
Location 3200 Cherry Creek Drive South
Denver, CO 80209
Phone [phone]

Also earnings out after the bell Friday, amazing results for this very very undervalued company
Forterus Announces Record Quarter Results http://www.stockmarketcats.com/f76/forterus-inc-fter-pink-quote-forterus-88033.html
Business Overview

Total revenue for the first quarter of 2010 grew 106% to $1,885,802 compared to $915,543 in the first quarter of 2009. Operating income for the first quarter increase 483% year over year to $199,132 compared to $34,105 in the first quarter of 2009. The Earnings Per Share (EPS) for the first quarter increased 550% to $.013 compared to $.002 in the first quarter of 2009. Revenue Per Share (RPS) increased 81% to $.123 compared to $.068 in the first quarter of 2009. The company had 15,324,864 shares outstanding at the end of the first quarter.

“2010 is off to a strong start for Forterus,” stated CEO Paul Howarth. “We achieved historical first quarter highs in revenue and earnings. Our ability to raise additional capital in the first quarter helped contribute to our increase in marketing and bed count which enabled us to achieve stronger than expected Q1 results.”
[Suppressed Image]

[snowgator69]

AMSZ after hour news!!!
AcuMedSpa Holdings, Inc. to Open Standalone Medical Spa in Coral Gables

TAMARAC, FL, Apr 14, 2010 (MARKETWIRE via COMTEX) -- AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, is pleased to announce that in an effort to further enhance the AcuMedSpa brand, the company plans on opening a standalone location in the heart of the Miracle Mile/Coral Gables shopping district (www.shopcoralgables.com), one of the most desired addresses in South Florida. This new location will provide all of AcuMedSpa's service offerings as well as include the services of a renowned South Florida plastic surgeon.
This location is expected to generate nearly $1,000,000.00 in annual revenue and will have the ability to provide up to 20 treatments at any given time. This location will rapidly become AcuMedSpa's "flagship" location.

With this location expected to open in late May or early June 2010, the company has decided to move out of its headquarters in Aventura, Florida; a move which will ultimately save us over $100,000 in rent and related expenses per year. Additionally the company expects to move the administrative staff to both our Tamarac and Coral Gables locations. AcuMedSpa is currently searching for an appropriate store front location in Aventura from which we will be able to offer our loyal customer base the high quality services they have become accustomed to.

We would also like to update the investment community on our progress with the previously stated pending acquisitions. We are meeting with our attorneys today to discuss the finalization procedure on the South Florida acquisition. As well, CEO Sperber will be travelling to Knoxville, TN later this week for meetings with the executive management team of Sohna and frequent their current locations.

Brian Sperber, President of AcuMedSpa summarized, "We expect our new standalone Coral Gables location to become our flagship location and the model for our continued expansion plans throughout South Florida and beyond. The space is beautiful and we expect to staff it with some of the best estheticians and medical professionals in South Florida. With this expansion we are another step closer to our goal of $10,000,000.00 in revenue in 2010 with an EBITDA of over $2,000,000.00."

[tech345]

AMHD volume seems to be picking up.

[MadeIt]

PGCX Daily Chart

[MadeIt]

Dr. Ronald Caputo, a PanGenex Board Member and one of America’s leading Interventional Cardiologists, stated, “The benefits of Omega-3 fatty acids have been well established through multiple extensive clinical studies. They have been demonstrated to lower the risk of sudden cardiac death and improve blood lipid profiles. Omega-3 fatty acids are also safe and well tolerated without serious side effects. As such, they are well accepted by both the medical community and the general public. What is not generally appreciated is that not all Omega-3 supplements provide equivalent benefit. There are major differences between products in regard to purity and formulation.

There are several unique features of Lipideme that make it superior to other Omega-3 products. Firstly, it provides an extremely high level of pure and well balanced Omega-3 fatty acids, far surpassing any other commercially available “fish oil” supplement of which I am aware. This is incredibly important in order to avoid the unnecessary and detrimental heavy metals and non-Omega-3 fats found in other products. Secondly, this proprietary formulation also incorporates the other well established natural lipid lowering agents phytosterols and tocotrienols - the natural “statins”. Thirdly, the inclusion of Co-enzyme Q adds an important anti-oxidant component to the compound.

As a high volume Interventional Cardiologist I am well acquainted with the results of untreated lipid abnormalities. I literally see blockages in coronary arteries every day. Lipideme provides an excellent option in the battle against coronary artery disease and I have seen significant clinical benefit in many patients from its use.” Dr. Caputo concluded.

About PanGenex Corporation

PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

[MadeIt]

Prominent Cardiologist Praises Efficacy of PanGenex' Lipideme
PanGenex Corporation (Pink Sheets: PGCX) (“PanGenex” or “the Company”) a global manufacturer and distributor of nutraceutical and dietary supplement products, today released a statement in response to the many inquiries about Omega-3 and Lipideme.

Dr. Ronald Caputo, a PanGenex Board Member and one of America’s leading Interventional Cardiologists, stated, “The benefits of Omega-3 fatty acids have been well established through multiple extensive clinical studies. They have been demonstrated to lower the risk of sudden cardiac death and improve blood lipid profiles. Omega-3 fatty acids are also safe and well tolerated without serious side effects. As such, they are well accepted by both the medical community and the general public. What is not generally appreciated is that not all Omega-3 supplements provide equivalent benefit. There are major differences between products in regard to purity and formulation.

There are several unique features of Lipideme that make it superior to other Omega-3 products. Firstly, it provides an extremely high level of pure and well balanced Omega-3 fatty acids, far surpassing any other commercially available “fish oil” supplement of which I am aware. This is incredibly important in order to avoid the unnecessary and detrimental heavy metals and non-Omega-3 fats found in other products. Secondly, this proprietary formulation also incorporates the other well established natural lipid lowering agents phytosterols and tocotrienols - the natural “statins”. Thirdly, the inclusion of Co-enzyme Q adds an important anti-oxidant component to the compound.

As a high volume Interventional Cardiologist I am well acquainted with the results of untreated lipid abnormalities. I literally see blockages in coronary arteries every day. Lipideme provides an excellent option in the battle against coronary artery disease and I have seen significant clinical benefit in many patients from its use.” Dr. Caputo concluded.

About PanGenex Corporation

PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. states, Canada, Puerto Rico, Canada, Brazil and Australia, in fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

[MadeIt]

PanGenex Corporation Issues Letter To Shareholders
PanGenex Corporation (Pink Sheets: PGCX) (“PanGenex” or “the Company”) issued the following letter to shareholders:

As President and CEO of PanGenex, a global manufacturer and distributor of nutraceutical and dietary supplement products, I am pleased to provide an update to our shareholders and the larger investing public regarding PanGenex' accomplishments to date, progress made over the recent months and our plans for 2010.

In 2009 PanGenex focused on core business fundamentals and near-term opportunities. Our focus had a major impact on how the business will scale as well as how shareholder value will increase. We have already completed several significant milestones that will be reflected in the balance sheet during 2010, some of which include;

-Q4 2009 Sales Demand Increased approximately 70% over Q3 and roughly 60% over Q4 2008.

-Q4 2009 bookings exceeded previous records, with approximately 74 percent of PanGenex’s recurring revenue resulting from on-line sales.

-added two of the most respected minds in cardiology to our Scientific Advisory Board in Dr. Peter Fitzgerald, MD, FACC and Dr. Louis Cannon MD, FACC.

-added a number of complementary alternative medicine (CAM)/holistic medical practitioners to our national physicians' referral network. These physicians are part of a national distribution channel for the Company's patented and patent pending nutraceutical products: Calci-Clear™, LIPIDEME™ and Omeganol™.

-the signing of a Multi Platform Sales Marketing Initiative with That’s Us Technologies, Inc.

-announced that without marketing emphasis, orders from Puerto Rico, Australia, Canada, Mexico and Brazil continue to be received by the Company.

Operational Efficiencies

Nutraceutical sales are on the rise, with several product segments experiencing 20% to 40% growth in 2009. In Q4 2009, demand for our Calci-Clear™ and LIPIDEME™ products which address widespread applications in the $538 Million Soft Tissue Calcification (STC) market, exceeded our short term ability to fill orders. While our inventory replenishment program was modeled after historical domestic growth rates, the unexpected foreign demand for our products necessitated that we adjust our supply chain partnerships. We expect to be positioned to fill all orders by April 5, 2010.”

Strategic Opportunities

We continue to seek partnerships and acquisitions that will further our footprint in the rapidly growing global nutraceutical market. The company is currently in the process of reviewing several strategic opportunities. The primary objective of any such transaction will be to accelerate our production, sales and distribution capabilities and to enhance our presence in some of the world’s fastest growing economies and markets.

I would like to take this opportunity to thank all employees of PanGenex Corporation for their hard work and dedicated service; to our shareholders for their loyal support and patience; and to our directors and officers who have maintained a strong belief and focus in what we are trying to accomplish. We look forward to a prosperous 2010 as we continue to develop our projects and implement strategies to increase shareholder value.

Sincerely,

John Stanton

About PanGenex Corporation

PanGenex Corporation pursues business opportunities in the $70 billion nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector-leading, patented or patent pending, condition-specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. PanGenex principal products Calci-Clear, LIPIDEME and Omeganol, address Soft Tissue Calcification (STC), an abnormal hardening or thickening of soft tissues (such as arteries) which is linked to over 50% of chronic diseases and presently affects an estimated 196 million or 60 percent of all Americans. Many of its products contain the purest grade of nutraceutical components available anywhere without a prescription. Since 2006, PanGenex has voluntarily submitted its product labels to the FDA without incidence. PanGenex products are sold to healthcare practitioners in 20 U.S. States, Canada, Puerto Rico, Canada, Brazil, Australia, fine retail establishments and on the Internet including: www.PanGenex.com, www.Calgenex.com and www.HeartHealthyWorld.com.

[MadeIt]

TECO.ob is extremely cheap right now

[InvestorSuisse]

IENT- New Game Release! First in Over 5 Years!!

Dogfights is available for $29.95 at Best Buy, Frye’s, MicroCenter, GoGamer, NewEgg, Hastings, and other retailers including Amazon.com!!

Dogfights is distributed by Interactive Gaming Software (IGS). For more information, visit www.igs-games.com.

[snowgator69]

EVPH - Everybody's Phone Company
Everybody's Phone Company offers local and long distance service on a prepaid basis. Specifically, local services include a "bare bones" product providing unlimited local dial tone and 911 emergency access with the option of several customer calling features, for an additional fee, including Call Waiting, Caller ID, Call Forwarding and Speed Dialing. These features may be purchased individually or in a package at reduced rates.

Everybody’s Phone Company purchases phone services from the incumbent local exchange carrier at deep discounts (currently up to 26%) and resells the service on a prepaid basis at a premium, allowing attractive profit margins. The markets are households without phone service due to lack of credit history or a poor credit history, and/or the inability to pay a deposit.

Share Statistics
Outstanding: 49,851,465 as of Mar 10, 2010
Float:
22,061,465 as of Mar 10, 2010